There is antiquated architecture for the real world that is now being applied to this area, says Cra. In our lab, we have safety, like, inother words, jus like bio safety level. And soan, if something gets flagged off, that there's a cycle that goes to engage with governments folks and stuff like that. But at the end of the day, i think cynthesis is not, you know, it could und up on people's bench tops,. It's not like a, it's not a great way to limit it, you know.
First Jason explains how to deliver great investor updates & the benefits of doing them well (1:36). Then, Ginkgo Bioworks CEO Jason Kelly joins to discuss the expanding capabilities of synthetic biology (24:48), how Ginkgo is currently helping customers make products more effectively (35:58), the ethics & risks of editing DNA (51:53) & more!